Insulet Launches Algorithm Improvements for Omnipod 5 AID System in US

Why It Matters

The enhanced algorithm gives clinicians and users finer glucose control and reduces manual interventions, strengthening Omnipod 5’s competitive edge in the fast‑growing AID market. Expanded sensor compatibility broadens the device’s ecosystem, potentially accelerating adoption among U.S. diabetes patients.

Key Takeaways

• Omnipod 5 now supports Abbott Libre 3 Plus sensor in US
• New algorithm adds six glucose targets, including 100 mg/dL
• OTA updates deliver features to existing pods and controllers
• Algorithm reduces Automated Mode interruptions during high glucose periods
• Insulet begins EVOLVE trial for fully closed‑loop system

Pulse Analysis

The latest Omnipod 5 upgrade arrives at a pivotal moment for automated insulin delivery (AID) technology. After securing FDA 510(k) clearance, Insulet’s new algorithm expands the therapeutic window by offering six customizable glucose targets, including a low 100 mg/dL setting. By prioritizing continuous Automated Mode operation even during prolonged hyperglycemia, the system reduces the need for manual bolusing, a key differentiator as competitors race to improve user autonomy and clinical outcomes.

Integration with Abbott’s FreeStyle Libre 3 Plus sensor further amplifies the system’s appeal. The sensor‑to‑pod link enables real‑time glucose data to flow into Abbott’s LibreLinkup app, giving patients and caregivers a unified view of therapy metrics. Over‑the‑air (OTA) updates mean existing Omnipod 5 users can instantly access the new algorithm and sensor compatibility without swapping hardware, lowering adoption friction and supporting a broader, more flexible diabetes management ecosystem in the United States.

Beyond the immediate software rollout, Insulet’s launch of the EVOLVE trial signals a strategic push toward a fully closed‑loop solution for type 2 diabetes. If successful, the trial could position Insulet as a leader in next‑generation AID platforms, expanding its addressable market beyond type 1 patients. The combination of algorithmic refinement, sensor interoperability, and forward‑looking clinical research underscores Insulet’s commitment to deepening its foothold in the rapidly expanding digital health and diabetes care sectors.